HUP0301330A2 - 2-Aminokarbonil-9H-purin-származékok - Google Patents

2-Aminokarbonil-9H-purin-származékok

Info

Publication number
HUP0301330A2
HUP0301330A2 HU0301330A HUP0301330A HUP0301330A2 HU P0301330 A2 HUP0301330 A2 HU P0301330A2 HU 0301330 A HU0301330 A HU 0301330A HU P0301330 A HUP0301330 A HU P0301330A HU P0301330 A2 HUP0301330 A2 HU P0301330A2
Authority
HU
Hungary
Prior art keywords
atom
things
group
alkyl group
alkyl
Prior art date
Application number
HU0301330A
Other languages
English (en)
Inventor
Simon John Mantell
Peter Thomas Stephenson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014048A external-priority patent/GB0014048D0/en
Priority claimed from GB0024920A external-priority patent/GB0024920D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0301330A2 publication Critical patent/HUP0301330A2/hu
Publication of HUP0301330A3 publication Critical patent/HUP0301330A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

A (I) általános képletű vegyületek, azok gyógyászatilag elfogadhatósói vagy szolvátjai, ahol a képletben R1 jelentése - egyebek mellett -H-atom vagy 1-6 szénatomos alkilcsoport, R2 jelentése - egyebekmellett - H-atom vagy 1-6 szénatomos alkilcsoport, R15 jelentése H-atom vagy 1-6 szénatomos alkilcsoport, R15 jelentése - egyebek mellett- H-atom vagy 1-6 szénatomos alkilcsoport, R3 jelentése - egyebekmellett - H-atom vagy 1-6 szénatomos alkilcsoport és R4 jelentése -egyebek mellett - azetidin-3-il-csoport, R5 jelentése CH2OH- vagy CONR14R14-csoport, m értéke 0, 1 vagy 2, Xjelentése - egyebek mellett - egyenesláncú 2-3 szénatomos, adottesetben 1-6 szénatomos alkil- vagy 3-8 szénatomos cikloalkilcsoporttalhelyettesített alkiléncsoport, Y jelentése CO-, CS-, SO2- vagyC=N(CN)-csoport. A találmány tárgyát képezik továbbá a találmányszerinti (I) általános képletű vegyületek, gyógyászatilag elfogadhatósók, szolvátok vagy készítmények gyógyszerként történő alkalmazásra ésezek előállítási eljárásai is. Ó
HU0301330A 2000-06-06 2001-06-05 2-aminocarbonyl-9h-purine derivatives HUP0301330A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014048A GB0014048D0 (en) 2000-06-06 2000-06-06 Purine derivatives
GB0018246A GB0018246D0 (en) 2000-06-06 2000-07-25 Purine derivatives
GB0024920A GB0024920D0 (en) 2000-06-06 2000-10-11 Purine derivatives
PCT/IB2001/000973 WO2001094368A1 (en) 2000-06-06 2001-06-05 2-aminocarbonyl-9h-purine derivatives

Publications (2)

Publication Number Publication Date
HUP0301330A2 true HUP0301330A2 (hu) 2003-08-28
HUP0301330A3 HUP0301330A3 (en) 2005-02-28

Family

ID=27255754

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301330A HUP0301330A3 (en) 2000-06-06 2001-06-05 2-aminocarbonyl-9h-purine derivatives

Country Status (34)

Country Link
EP (1) EP1292604B1 (hu)
JP (2) JP4129176B2 (hu)
KR (1) KR100484704B1 (hu)
CN (1) CN1249074C (hu)
AR (1) AR030289A1 (hu)
AT (1) ATE431356T1 (hu)
AU (2) AU2001260537B2 (hu)
BG (1) BG107216A (hu)
BR (1) BR0111263A (hu)
CA (1) CA2414018C (hu)
CU (1) CU23240B7 (hu)
CZ (1) CZ20023875A3 (hu)
DE (1) DE60138702D1 (hu)
DK (1) DK1292604T3 (hu)
DZ (1) DZ3439A1 (hu)
EA (1) EA004983B1 (hu)
EE (1) EE200200678A (hu)
ES (1) ES2324816T3 (hu)
GC (1) GC0000287A (hu)
HK (2) HK1054042A1 (hu)
HR (1) HRP20020960A2 (hu)
HU (1) HUP0301330A3 (hu)
IL (2) IL152783A0 (hu)
IS (1) IS6599A (hu)
MA (1) MA26910A1 (hu)
MX (1) MXPA02012033A (hu)
NO (1) NO324426B1 (hu)
NZ (1) NZ522184A (hu)
OA (1) OA12279A (hu)
PA (1) PA8518801A1 (hu)
PL (1) PL360435A1 (hu)
SK (1) SK16752002A3 (hu)
TW (1) TWI227240B (hu)
WO (1) WO2001094368A1 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
CA2460911C (en) 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
ATE381336T1 (de) * 2002-04-10 2008-01-15 Univ Virginia Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US20060178403A1 (en) * 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7067509B2 (en) 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005040174A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2440317T3 (es) 2006-04-21 2014-01-28 Novartis Ag Derivados de purina para su uso como agonistas del receptor de adenosina A2A
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
PT2297114T (pt) 2008-06-19 2018-07-26 Takeda Pharmaceuticals Co Composto heterocíclico e a sua utilização
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
WO2010136940A1 (en) 2009-05-29 2010-12-02 Pfizer Limited Novel glucocorticoid receptor agonists
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
IN2012DN01453A (hu) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121372B1 (en) * 1998-10-16 2006-06-28 Pfizer Limited Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
EE200200678A (et) 2004-06-15
KR20030032962A (ko) 2003-04-26
IS6599A (is) 2002-10-29
GC0000287A (en) 2006-11-01
KR100484704B1 (ko) 2005-04-22
EA004983B1 (ru) 2004-10-28
CZ20023875A3 (cs) 2004-02-18
EP1292604A1 (en) 2003-03-19
EP1292604B1 (en) 2009-05-13
ATE431356T1 (de) 2009-05-15
ES2324816T3 (es) 2009-08-17
PA8518801A1 (es) 2002-09-17
MXPA02012033A (es) 2003-04-25
IL184144A0 (en) 2007-10-31
OA12279A (en) 2003-01-01
JP2003535871A (ja) 2003-12-02
IL184144A (en) 2008-11-26
MA26910A1 (fr) 2004-12-20
AU2001260537B2 (en) 2006-05-25
AU6053701A (en) 2001-12-17
PL360435A1 (en) 2004-09-06
NZ522184A (en) 2004-05-28
NO20025821D0 (no) 2002-12-04
BR0111263A (pt) 2003-06-17
JP4129176B2 (ja) 2008-08-06
CN1434830A (zh) 2003-08-06
HUP0301330A3 (en) 2005-02-28
DZ3439A1 (fr) 2001-12-13
AR030289A1 (es) 2003-08-20
SK16752002A3 (sk) 2004-05-04
CU23240B7 (es) 2007-10-17
HK1089447A1 (en) 2006-12-01
CA2414018A1 (en) 2001-12-13
CA2414018C (en) 2007-10-16
DE60138702D1 (de) 2009-06-25
HK1054042A1 (en) 2003-11-14
HRP20020960A2 (en) 2005-02-28
IL152783A0 (en) 2003-06-24
DK1292604T3 (da) 2009-06-15
BG107216A (bg) 2003-05-30
CN1249074C (zh) 2006-04-05
TWI227240B (en) 2005-02-01
NO324426B1 (no) 2007-10-08
EA200201179A1 (ru) 2003-04-24
WO2001094368A1 (en) 2001-12-13
NO20025821L (no) 2003-02-04
JP2008150383A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
HUP0301330A2 (hu) 2-Aminokarbonil-9H-purin-származékok
HUP0302962A2 (hu) Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
HUP0202017A2 (hu) Új vegyületek
HUP0302943A2 (hu) Új heterociklusos vegyületek, előállításuk és alkalmazásuk gyógyszerekként, különösen antibakteriális szerekként
HUP0401083A2 (hu) 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0104867A2 (hu) Gyulladásos betegségek kezelésére használható heterociklusos vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP0302468A2 (hu) Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
MX9603593A (es) Derivados de quinazolina.
ES2190469T3 (es) Derivados de isocumarina y su uso en farmacos.
ATE131481T1 (de) Metalloporphyrinderivate, ihre herstellung, ihre therapeutische anwendung und ihre anwendung zur herstellung von hybridischen molekülen
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
DE69305276D1 (de) Arylglycinamidderivate, Verfahren zur deren Herstellung und deren Verwendung zur Therapie der Dysurie
HUP9903632A2 (hu) Neuraminsav vegyületek, azokat tartalmazó gyógyszerkészítmények és eljárás e készítmények előállítására
DK0534904T3 (da) Imidazolylmethyl-pyridiner
WO1999021848A3 (en) Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
HUP0105426A2 (hu) 3-(2-oxo-[1,3']bipirrolidinil-3-ilidén-metil)-cefém-származékok és ezeket tartalmazó gyógyszerkészítmények
ATE104294T1 (de) Antipsychotische verbindungen.
DE3752272D1 (de) Verwendung eines Thioesters zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Ischämie und von Reperfusion-Syndromen
HUP9803028A2 (hu) Ciklusos nitronok és az azokat hatóanyagként tartalmazó gyógyszerkészítmények
DE69030502D1 (de) Cephalosporinverbindungen und deren herstellung
DE69315363D1 (de) Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel
ATE340155T1 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon
DE69301639D1 (de) Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung
HUP0202663A2 (hu) 7-acilamino-3-heteroariltio-3-cefémkarbonsav antibiotikumok és prodrogjaik, előállításuk és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished